New study arm in rEECur trial with Trabectedin for relapsed Ewing sarcoma

Birmingham/Manchester, UK, January 21, 2026

Ewing sarcoma, a rare bone and soft tissue cancer in children and young adults has poor outcomes at relapse. The drug trabectedin offers a hopeful new option for treatment. Patient advocates have collaborated with investigators and the manufacturer of trabectedin, to open a new treatment arm containing trabectedin within rEECur, the largest international randomised trial in relapsed Ewing sarcoma. This development will offer additional options for patients with limited treatment alternatives. The treatment arm is planned to open in the UK and internationally later this year.